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Introduction
Directed cell migration is fundamental to many biological pro-
cesses, including embryogenesis, wound healing, the immune 
response, and cancer metastasis (Ridley et al., 2003). This pro-
cess is initiated in response to extracellular or internal cues and 
is driven by the localized polymerization of F-actin, leading to 
cell polarization, the extension of a leading edge lamellipodium, 
and migration in the direction of the leading edge (Small et al., 
2002; Pollard and Borisy, 2003).
F-actin assembly is induced in response to the localized   
activation of Rac1 at the leading edge (Nobes and Hall, 1999; 
Kraynov et al., 2000; Wheeler et al., 2006). In turn, Rac1 initiates 
and maintains polarized protrusive activity by stimulating Arp2/3-
dependent de novo actin nucleation and by generating free barbed 
actin filament ends (Takenawa and Miki, 2001; Small et al., 2002; 
Pollard and Borisy, 2003). Rac1 also promotes the formation of 
nascent  focal  adhesion  complexes,  which  stabilize  membrane 
protrusions and generate the traction force necessary for migration 
(Nobes and Hall, 1999; Pankov et al., 2005; Guo et al., 2006;   
Vidali et al., 2006). Therefore, the localization of Rac1 activity to 
specific membrane domains is critical for directional migration, 
but the underlying mechanisms are poorly understood.
Rac1, like other small GTPases, undergoes cycles of activa-
tion and deactivation that are catalyzed by GTP exchange factors 
(GEFs) and GTPase-activating proteins in response to growth fac-
tor and integrin receptor signaling pathways (Etienne-Manneville 
and Hall, 2002; Rossman et al., 2005). Rac1 signaling is also con-
trolled through the regulated translocation of Rac1 from a cytosolic 
pool to the plasma membrane (del Pozo et al., 2002). This event is 
induced in response to integrin-mediated adhesion of cells and   
is essential for Rac1 coupling to downstream effectors (del Pozo   
et al., 2000, 2002). Because activated integrins are concentrated at 
the cell front (Moissoglu and Schwartz, 2006), the integrin-induced 
subcellular targeting of Rac1 is likely to play a key role in cellular 
processes that depend on the polarized activation of Rac1, such as 
directed cell migration. However, the mechanisms that control the 
targeting of Rac1 to the plasma membrane and the significance of 
this process for cell migration are unclear.
P
hosphatidylinositol-4,5-bisphosphate (PI4,5P2) is   
a critical regulator of cell migration, but the roles   
of  the  type  I  phosphatidylinositol-4-phosphate   
5-kinases (PIPKIs), which synthesize PI4,5P2, have yet to 
be fully defined in this process. In this study, we report that 
one kinase, PIPKI-, is a novel upstream regulator of Rac1 
that links activated integrins to the regulation of cell mi-
gration. We show that PIPKI- controls integrin-induced 
translocation  of  Rac1  to  the  plasma  membrane  and 
thereby regulates Rac1 activation. Strikingly, this function 
is not shared with other PIPKI isoforms, is independent   
of catalytic activity, and requires physical interaction of 
PIPKI- with the Rac1 polybasic domain. Consistent with 
its role in Rac1 activation, depletion of PIPKI- causes 
pronounced defects in membrane ruffling, actin organi-
zation, and focal adhesion formation, and ultimately af-
fects the directional persistence of migration. Thus, our 
study defines the role of PIPKI- in cell migration and de-
scribes  a  new  mechanism  for  the  spatial  regulation  of 
Rac1 activity that is critical for cell migration.
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Figure 1.  PIPKI- is required for adhesion-induced Rac1 plasma membrane targeting. (A) HeLa cells were incubated for 20 min with 5 µm FN- or BSA-
coated beads shown in the phase-contrast image (differential interference contrast [DIC]) and marked by arrows. Cells were fixed and stained with Alexa 
Fluor 647 phalloidin to visualize F-actin or with appropriate primary and secondary antibodies to detect endogenous PIPKI- and Rac1. (B) HeLa cells, 
transiently transfected with GFP–PLC-–PH as a marker for PI4,5P2, were incubated with FN- or BSA-coated beads as described above, and GFP fluores-
cence and DIC images were recorded. (C) Cells transfected with control siRNAs or siRNAs targeting PIPKI-, -, -, or Rac1 were incubated with FN-coated 
beads, fixed, and stained as described in A. (right) Fluorescence intensity profiles showing the extent of marker colocalization were determined along the 
lines. Colors indicate PIPKI- (red), Rac1 (green), and F-actin (blue) fluorescence. Images in A–C are representative examples of three separate experiments.   
(D) Subcellular fractionation of HeLa cell lysates into particulate (P) and soluble (S) fractions. HeLa cells transfected with the indicated siRNA pools were plated 
on FN-coated substrate and serum starved to eliminate contribution from growth factor signals. Cell lysates were generated, subfractionated into 100,000 g 
pellet (P100; membrane) and supernatant (S100; cytosol) fractions, and analyzed by Western blotting with antibodies against PIPKI- and Rac1. EGFR and 
RhoGDI were detected as markers for membrane and cytosol fractions, respectively. A representative experiment is shown. Note that the amount of protein 249 Type I PIPK- regulates Rac1 activation • Chao et al.
incubated HeLa cells with 5 µm polystyrene beads coated with 
fibronectin (FN), which induce the local activation and cluster-
ing of integrins at the cell surface (del Pozo et al., 2002). As pre-
viously  reported  (del  Pozo  et  al.,  2002),  FN-coated  but  not 
BSA-coated control beads resulted in the accumulation of endog-
enous Rac1 and F-actin at bead–cell contact sites (Fig. 1 A).
 FN-coated beads also led to the clustering of endogenous PIPKI- 
and the up-regulation of PI4,5P2 synthesis at bead–cell contact 
sites, as revealed by the localization of a GFP–PLC-–pleckstrin 
homology (PH) reporter protein (Fig. 1 B). Significantly, Rac1 
clustering and F-actin assembly at bead–cell contact sites were 
markedly decreased by RNAi-mediated knockdown of PIPKI- 
(Fig. 1 C), suggesting that integrin-induced Rac1 translocation 
to the membrane needs PIPKI-. This was revealed by measur-
ing the ratio of mean GFP pixel density at bead–cell contact sites 
relative to beadless areas on the membrane. This analysis showed 
that 87 ± 5% of beads on control siRNA–treated cells induced 
increased Rac1 membrane signal (n = 45), whereas only 11 ± 
3% of beads (n = 55) induced Rac1 signal in PIPKI-–depleted 
cells, and even around the positive beads, the signal intensity 
was significantly decreased (Fig. 1 C). The loss of Rac1 mem-
brane recruitment in PIPKI-–depleted cells was confirmed   
by biochemical fractionation experiments, which revealed a   
decrease in Rac1 protein levels in the particulate, membrane-
containing fraction (Fig. 1, D and E). Conversely, depletion of 
Rac1 did not markedly affect the membrane association of 
PIPKI-, as judged by biochemical (Fig. 1, D and E) and immuno-
fluorescence experiments (Fig. 1 C).
Notably, the role of PIPKI- in Rac1 membrane targeting 
was isoform specific. Neither PIPKI- nor PIPKI- expression 
was necessary for Rac1 accumulation at bead–cell contact sites, 
as 80 ± 6% of beads in PIPKI-–depleted cells (n = 38) and 82 ± 
7% of beads in PIPKI-–depleted cells (n = 34) had increased 
Rac1 signal when compared with beadless areas (Fig. 1 C). Col-
lectively, these data suggest that integrin-dependent membrane 
translocation of Rac1 is dependent on PIPKI-. The finding that 
endogenous Rac1 localized with PIPKI- at actin-rich membrane 
ruffles in control cells but became delocalized from the plasma 
membrane upon depletion of PIPKI- (Fig. S2) further supports 
the idea that Rac1 membrane localization requires PIPKI-.
Integrin-dependent Rac1 membrane 
targeting involves the polybasic domain  
of Rac1
It was previously reported that the polybasic domain of Rac1 me-
diates the integrin-dependent translocation of Rac1 to the mem-
brane (del Pozo et al., 2002; van Hennik et al., 2003). Consistent 
with this, a Rac1 variant containing a single amino acid mutation 
(K186A) within the polybasic domain failed to efficiently accu-
mulate at FN–bead–cell contact sites in HeLa cells (Fig. 2 A). 
However, other regions in the hypervariable C-terminal domain 
of Rac1 have also been reported to modulate Rac1 targeting and 
Recently, Rac1 was reported to form a complex with two 
members of the type I phosphatidylinositol-4-phosphate 5-kinase 
(PIPKI) family, designated PIPKI- and PIPKI- (Tolias et al., 
1998, 2000; van Hennik et al., 2003). PIPKIs synthesize the sig-
naling molecule phosphatidylinositol-4,5-bisphosphate (PI4,5P2), 
which is a central regulator of actin and adhesion dynamics during 
cell migration (Yin and Janmey, 2003; Ling et al., 2006). Interest-
ingly, Rac1 binds the two kinases independent of its GTP-loading 
status through its C-terminal polybasic domain (Tolias et al., 1998, 
2000). This hypervariable region is distal to the effector-binding 
domains of Rac1 and is positioned just upstream of the CAAX 
box that mediates the attachment of a lipid anchor. PIPKI–Rac1 
complex formation via this domain is necessary for stimulation of 
PI4,5P2 synthesis and actin assembly (Tolias et al., 1998, 2000). 
Thus, PIPKI- and PIPKI- are widely thought to be effectors of 
Rac1. Consistent with such an idea, PI4,5P2 synthesis and actin 
filament uncapping, which are induced in response to expression 
of constitutively active Rac1
V12, could be blocked by simultaneous 
expression of a dominant-negative PIPKI- mutant (Tolias et al., 
1998, 2000). Surprisingly, expression of a corresponding kinase-
dead mutant of PIPKI- had no inhibitory effect on Rac1
V12  
signaling to the actin cytoskeleton (Tolias et al., 1998, 2000; van 
Hennik et al., 2003). This finding raised the possibility that the 
roles of PIPKI- and PIPKI- in the Rac1 pathway are not equiva-
lent and that the physiological significance of the PIPKI-–Rac1 
interaction remains yet to be established.
Intriguingly, recent evidence suggests that the PIPKI- 
interaction domain in Rac1 controls the subcellular targeting 
and activation of Rac1 in response to integrin-mediated adhe-
sion (del Pozo et al., 2002; van Hennik et al., 2003). Accord-
ingly, Rac1 mutants in the polybasic domain fail to translocate 
to the plasma membrane and also fail to activate downstream 
signaling responses (del Pozo et al., 2002). Given that the same 
mutations  in  the  Rac1  polybasic  domain  that  prevent  Rac1 
membrane targeting also abrogate the Rac1–PIPKI- inter-
action (Tolias et al., 2000), the question arises as to whether the 
PIPKI-–Rac1 interaction provides a means to regulate the lo-
calization of Rac1 activity.
In this study, we present evidence in support of such a   
hypothesis. We show that PIPKI- plays a pivotal, isoform- 
specific role in regulating the translocation of Rac1 to the 
plasma membrane. Furthermore, we show that PIPKI- thereby 
regulates Rac1 activation and downstream signaling processes 
necessary for F-actin assembly, focal adhesion formation, and 
directed cell migration.
Results
PIPKI- is necessary for adhesion-induced 
Rac1 membrane translocation
To examine whether PIPKI- modulates the localization of Rac1 
to the plasma membrane in response to integrin activation, we 
analyzed per lane represents 5% of the total soluble fraction but 20–50% of the particulate fraction. (E) Quantification of Rac1 membrane localization by 
quantitative Western blot (WB) analysis from D is shown. Data are normalized according to the total levels of each marker and the calculated percentage 
in the membrane fraction. Values are means from two independent experiments. Error bars indicate SEM. Bars, 10 µm.
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Rac1 membrane association is also regulated by Rho 
guanine nucleotide dissociation inhibitor (RhoGDI), which 
extracts Rac1 from the plasma membrane (del Pozo et al., 
2002; Dransart et al., 2005; Moissoglu and Schwartz, 2006). 
However, a Rac1 mutant (Rac1
Q66A) that is unable to bind 
RhoGDI  accumulated  in  a  manner  similar  to  wild-type   
Rac1 around FN–bead–cell contact sites (Fig. 2 A). Thus, 
RhoGDI  does  not  contribute  to  the  effects  of  PIPKI-  on 
Rac1 membrane targeting. This conclusion was further sup-
ported by biochemical and immunofluorescence experiments 
that showed that endogenous RhoGDI is predominantly cyto-
solic (Fig. 1, D and E) and not detected at bead–cell contact 
sites (Fig. 2 B).
activation. In particular, a proline-rich motif adjacent to the poly-
basic domain is required for Rac1 association with the Rac1 GEF 
-PIX (van Hennik et al., 2003; ten Klooster et al., 2006), and 
this interaction has been implicated in targeting Rac1 to focal   
adhesions and in mediating Rac1 activation (ten Klooster et al., 
2006). Therefore, we examined the localization of a Rac1 mutant, 
designated Rac1(Pro), which is defective for -PIX binding 
(ten Klooster et al., 2006). As shown in Fig. 2 A, this mutant local-
ized as efficiently as wild-type Rac1 to FN–bead–cell contact sites 
but appeared to attenuate actin assembly around beads. These re-
sults suggest that Rac1 membrane targeting can occur indepen-
dently of -PIX, but subsequent activation of Rac1 at the 
membrane may require interaction with -PIX.
Figure 2.  Integrin-mediated translocation of Rac1 to the membrane involves the polybasic domain of Rac1. (A) HeLa cells expressing the indicated GFP-
tagged Rac1 wild-type (wt) or mutant variants were incubated with FN-coated beads for 20 min (shown in the phase-contrast image; DIC). Cells were 
fixed and stained with appropriate antibodies to visualize endogenous PIPKI- (I) and with Alexa Fluor 647–conjugated phalloidin to visualize actin. 
GFP fluorescence was recorded directly. Fluorescence intensity profiles showing the extent of GFP (green), PIPKI- (red), and F-actin (blue) colocalization 
were determined along the lines drawn and are shown to the right. (B) HeLa cells were incubated with FN-coated beads for 20 min. Cells were fixed and 
immunostained for endogenous RhoGDI. Actin was visualized with Alexa Fluor 647–conjugated phalloidin. (right) Line scans of fluorescence intensity of 
RhoGDI (green) and F-actin (blue) signals are shown. Images are representative examples of three separate experiments. Bars, 10 µm.251 Type I PIPK- regulates Rac1 activation • Chao et al.
Figure 3.  Adhesion-induced Rac1 plasma membrane translocation requires PIPKI- protein but not polyphosphoinositide synthesis. (A) PIPKI-–depleted 
HeLa cells transfected with Flag-IKD or empty vector (top) were incubated with FN-coated beads for 20 min, fixed, and stained with appropriate primary 
and secondary antibodies to visualize the Flag epitope and endogenous Rac1, respectively. F-actin was stained with Alexa Fluor 647 phalloidin. Fluores-
cence and DIC images are shown. Fluorescence intensity profiles showing the extent of Flag-IKD (red), Rac1 (green), and F-actin (blue) colocalization 
were determined along the line drawn and are shown to the right. (B) HeLa cells were pretreated with 10 mM neomycin (Neo), 50 µM LY294002 (LY), 
or the combination of neomycin and LY294002 (Neo + LY). Cells were incubated with FN-coated beads for 20 min, fixed, and stained with Alexa Fluor 
647 phalloidin or the appropriate primary and secondary antibodies to detect endogenous PIPKI- and Rac1, respectively. (right) Fluorescence intensity 
profiles showing the extent of Flag–PIPKI- (red), Rac1 (green), and F-actin (blue) colocalization were determined along the line drawn. (C and D) HeLa 
cells transfected with EGFP–PLC-–PH (C) or EGFP-AKT-PH (D) were treated with vehicle (DMSO; top) or 10 mM neomycin (C, bottom) for 60 min or with 
50 µM LY294002 for 20 min (D, bottom). Cells were incubated with FN-coated beads as described above and stained with Alexa Fluor 594 phalloidin 
after fixation. Fluorescence and DIC images were recorded directly. Bars, 10 µm.JCB • VOLUME 190 • NUMBER 2 • 2010   252
2006). To distinguish between these two possibilities, we tested 
whether integrin-induced Rac1 membrane recruitment could be 
restored to PIPKI-–depleted cells by reexpression of a PIPKI- 
mutant  (IKD)  lacking  catalytic  activity.  Consistent  with  a   
kinase-independent  role  of  PIPKI-  in  Rac1  plasma  mem-
brane targeting, we found that expression of IKD restored the 
PIPKI- controls Rac1 membrane targeting 
through a kinase-independent mechanism
We  next  examined  whether  the  polybasic  domain  of  Rac1   
mediates membrane targeting through direct physical interaction 
with PIPKI- or through binding to PI4,5P2 or PI3,4,5P3 as 
shown for other small GTPases (Ueyama et al., 2005; Heo et al., 
Figure 4.  PIPKI- modulates Rac1 subcellular localization through the Rac1 polybasic domain. HeLa cells were cotransfected with mitochondrially   
targeted EGFP-tagged PIPK variants (I-Mito, I-Mito, or I661-Mito) and plasmids encoding Flag-tagged wild-type or mutant Rac1 variants or RhoA.   
Cells were fixed and stained with mouse anti-Flag antibody followed by Cy3-conjugated goat anti–mouse antibodies. GFP signal was recorded directly. 
(right) Fluorescence intensity profiles showing the extent of Flag (red) and EGFP (green) colocalization were determined along the line drawn. Representative 
examples of cells are shown (n = 3). Bar, 10 µm.253 Type I PIPK- regulates Rac1 activation • Chao et al.
fusions GFP–PLC-–PH and GFP-Akt-PH (Fig. 3, C and D), 
which are biosensors for PI4,5P2 and PI3,4,5P3, respectively 
(Balla Várnai, 2002). Thus, synthesis of PI4,5P2 and PI3,4,5P3 is 
necessary for adhesion-dependent F-actin polymerization but 
dispensable for Rac1 plasma membrane targeting.
PIPKI- modulates Rac1 subcellular 
targeting through interaction with the 
Rac1 polybasic domain
To test whether PIPKI- directly controls the subcellular local-
ization of Rac1, we targeted PIPKI- to the surface of mitochon-
dria away from the site of normal PIPKI- and Rac1 localization 
by fusing PIPKI- to the transmembrane domain of the outer 
mitochondrial membrane protein OMP25 (Nemoto and De   
Camilli,  1999).  When  I-Mito  was  coexpressed  with  Flag-
tagged Rac1 in HeLa cells, Rac1 protein was sequestered to mi-
tochondria (Fig. 4 A). Rac1 was also recruited to mitochondria 
accumulation of endogenous Rac1 signal at FN–bead–cell con-
tact sites in PIPKI-–depleted cells (Fig. 3 A). IKD expres-
sion also partially restored F-actin polymerization at these sites 
(Fig. 3 A), suggesting that PIPKI- stimulates adhesion-dependent 
actin polymerization in part through its effect on Rac1. No Rac1 
or F-actin signal was observed at FN–beads in cells transfected 
with empty vector (Fig. 3 A). Thus, PIPKI- appears to control 
adhesion-induced Rac1 membrane targeting independently of 
its lipid kinase activity.
Consistent  with  this,  the  pharmacological  inhibition   
of PI4,5P2 or PI3,4,5P3 production by treatment of cells with   
the PI4,5P2-sequestering agent neomycin or the phosphatidyl-
inositol 3-kinase inhibitor LY294002, either alone or in combi-
nation, had no effect on Rac1 clustering around FN-coated beads 
(Fig. 3 B). These treatments were effective because they led to 
a significant reduction in F-actin assembly (Fig. 3 B) and caused 
the delocalization from the plasma membrane of the PH domain 
Figure 5.  PIPKI- is necessary for Rac1 activation. (A) Rac1 activation in response to attachment and spreading of HeLa cells on FN substrate or BSA. Cells 
were plated on FN or BSA for the indicated times, lysed, and Rac1-GTP present in the cell lysates was isolated by pull-down assay using PBD-PAK1-GST. 
Total and GTP-bound Rac1 were detected by Western blotting. (B) Rac1 activity in HeLa cells transfected with control siRNAs or siRNAs targeting either 
PIPKI- or PIPKI- are shown. Mock-treated () or siRNA-treated (+) cells were allowed to attach to FN for 20 min. Rac1-GTP was isolated from cell lysates 
and detected along with total Rac1 protein as described above. (C) Quantification of Rac1-GTP levels from B is shown. (D) Rac1 activation in response to 
PDGF treatment. Quiescent control or PIPKI-–depleted HT1080 cells grown on plastic dishes were stimulated with 10 ng/ml PDGF (+) or left untreated (). 
Rac1-GTP was isolated from cell lysates and detected along with total Rac1 protein by Western blotting as described in A. (E) A quantification of the ratios 
of GTP-bound to total Rac1 protein from D is shown. Values are normalized to control, and error bars indicate SEM (n = 3).JCB • VOLUME 190 • NUMBER 2 • 2010   254
Figure 6.  PIPKI- modulates Rac1 activation by regulating Rac1 membrane translocation. (A) Rac1-GTP is contained in the membrane fraction. HT1080 
cells were plated on FN and serum starved to eliminate contribution from growth factor signals. Cell lysates were generated and fractionated into particu-
late (P) and soluble (S) fractions, and Rac1-GTP levels were determined. A representative example (n = 3) of Rac1-GTP and total Rac1 levels as detected by 
Western blot analysis using anti-Rac1 antibody is shown. (B) Enhanced membrane targeting restores integrin-dependent Rac1-GTP loading to PIPKI-–deficient 
cells. Quiescent control or PIPKI-–depleted HT1080 cells expressing Lyn-EGFP-Rac1 (Lyn-Rac1) were plated on FN, and GTP-loaded Lyn-EGFP-Rac1 was 
isolated from cell lysates by pull-down assay. Lyn-Rac1-GTP, total Lyn-Rac1, and endogenous PIPKI- levels were detected by Western blot analysis using 255 Type I PIPK- regulates Rac1 activation • Chao et al.
Rac1-GTP loading by pull-down assay with the p21-binding 
domain of PAK1 kinase (Benard and Bokoch, 2002). As ex-
pected (del Pozo et al., 2000), attachment of HeLa cells to FN 
substrate stimulated a significant increase in Rac1-GTP levels 
in control siRNA–treated cells within a 10- to 20-min period 
relative to cells plated on BSA (Fig. 5, A and B). In contrast, lit-
tle stimulation of Rac1-GTP loading was observed in PIPKI- 
knockdown cells plated on FN (Fig. 5, B and C). Importantly, 
PIPKI-–depleted cells exhibited an increase in Rac1-GTP lev-
els in response to FN, which is similar to control cells (Fig. 5,   
B and C). Thus, PIPKI- plays a unique role in the integrin-
stimulated activation of Rac1.
To determine whether PIPKI- also regulates Rac1 acti-
vation in response to growth factor activation of cells, we mea-
sured Rac1-GTP levels in response to PDGF. We switched to 
HT1080 cells for these experiments because these cells respond 
to PDGF and the role of PIPKI- in adhesion-induced Rac1 
membrane targeting, and activation is conserved (unpublished 
data). We found that PDGF treatment of quiescent control but 
not of PIPKI-–depleted cells stimulated Rac1-GTP loading 
(Fig. 5, D and E). Therefore, PIPKI- appears to be necessary 
for both growth factor– and adhesion-induced Rac1 activation.
Finally, we aimed at elucidating how PIPKI- affects 
Rac1 activity. PI4,5P2 is the precursor of PI3,4,5P3, which acti-
vates several of the known Rac1 GEFs, including Dock180, 
Vav, and Tiam (Han et al., 1998; Baumeister et al., 2003; Côté 
et al., 2005). Thus, one way by which PIPKI- depletion may 
block Rac1 activation is by decreasing GEF activity. Alterna-
tively, the PIPKI-–dependent targeting of Rac1 to the plasma 
membrane may be a prerequisite for its interaction with a 
membrane-localized GEF (Moissoglu et al., 2006). Consis-
tent with the latter concept, we found that only the membrane, 
but not the cytosol fraction from adherent HT1080 (Fig. 6 A) 
or HeLa cells (unpublished data), contained Rac1-GTP. To 
further assess whether PIPKI- regulates Rac1-GTP loading 
through its effects on Rac1 membrane targeting, we exam-
ined whether we could bypass the requirement for PIPKI- 
and restore Rac1 activation by artificially increasing Rac1 
plasma membrane levels. To do so, we engineered a variant of 
Rac1 that contained a second plasma membrane–anchoring 
in cells that expressed a PIPKI- kinase-dead mutant (IKD-
Mito; Fig. 4 A), indicating that Rac1 sequestration to mitochon-
dria required physical interaction with PIPKI- but not its 
catalytic activity. Indeed, there appeared to be a direct correlation 
between the ability to bind Rac1 with high affinity in vitro and the 
ability to modulate Rac1 subcellular targeting in the mitochon-
drial sequestration assay. Accordingly, PIPKI-, which bound 
Rac1 with lower apparent affinity relative to PIPKI- (Fig. S3 B), 
was much less efficient in sequestering Rac1 to mitochondria 
(Fig. 4 A), and PIPKI-, which failed to bind Rac1 in vitro   
(Fig. S3 B), failed to recruit Rac1 to mitochondria (Fig. 4 A).
Importantly, the Rac1 polybasic domain was not only nec-
essary but also sufficient to induce the mitochondrial sequestra-
tion of Rac1. Thus, the Rac1(PQ) or Rac1(K186A) mutations   
in the Rac1 polybasic domain that abrogated binding to PIPKI- 
in vitro (Fig. S3 C) also prevented the recruitment of Rac1 to mito-
chondria (Fig. 4). Conversely, a RhoA-Rac1 chimera, which con-
tained the polybasic region of Rac1, efficiently bound PIPKI- 
in vitro (Fig. S3 D) and colocalized with I-Mito to mitochon-
dria, whereas wild-type RhoA failed to do so (Fig. 4). Collectively, 
these  results  suggest  that  the  mitochondrial  sequestration  of 
Rac1 is dependent on its direct interaction with PIPKI-, al-
though we cannot exclude the possibility that an unknown dock-
ing factor mediates the interaction between PIPKI- and Rac1.
Notably, expression of I-Mito also caused the sequestra-
tion of endogenous Rac1 to mitochondria and the concomitant 
inhibition of chemotaxis compared with cells transfected with 
empty vector (Fig. S4, A and B). Because the chemotaxis defect 
induced by overexpression of I-Mito could be suppressed by 
simultaneous overexpression of Rac1, these results suggest that 
the PIPKI-–directed mislocalization of Rac1 attenuated Rac1 
signaling (Fig. S4 C). These data show that PIPKI- can modu-
late Rac1 function by regulating its subcellular localization.
PIPKI- regulates Rac1 activation by 
modulating Rac1 membrane targeting
Integrins independently regulate Rac1 plasma membrane tar-
geting and GTP loading (del Pozo et al., 2002). To determine 
whether PIPKI- depletion only affects adhesion-induced Rac1 
membrane  translocation  or  also  its  activation,  we  measured 
antibodies against GFP and Rac1. A representative example (n = 3) is shown. (C) The extent of integrin-induced Rac1-GTP loading correlates with Rac1 
membrane association. PIPKI-–depleted HT1080 cells transfected with plasmids expressing EGFP-tagged Lyn-Rac1, wild-type (wt) Rac1, or Rac1CAAX were 
plated on FN substrate, serum starved, and Rac1-GTP was isolated by pull-down assay from cell lysates. EGFP–Rac1-GTP and total EGFP-Rac1 protein were 
detected by Western blot (WB) analysis of cell lysates using an anti-GFP antibody. To detect EGFP-Rac1 protein associated with membranes, aliquots of 
the same cell lysates were fractionated into particulate (P100) and soluble (S100) fractions, and EGFP-Rac1 in the P100 fraction was detected by Western 
blot analysis. Representative examples of Western blots (n = 3) are shown. (D and E) Quantitation of total EGFP–Rac1-GTP levels present in the cell lysate 
(D) and of EGFP-Rac1 protein levels present in the P100 fraction (E) are shown as calculated from C. EGFP–Rac1-GTP levels in D are expressed relative to 
those of total EGFP-Rac1 and levels were normalized relative to those of Lyn-Rac1, which were arbitrarily set to 100%. EGFP-Rac1 levels in the P100 fraction 
(E) are expressed relative to those of total EGFP-Rac1 and levels were normalized relative to those of Lyn-Rac1, which were arbitrarily set to 100%. Values 
indicate SEM (n = 3). (F) Integrin engagement induces membrane translocation of PIPKI- and Rac1. Cell lysates were generated from quiescent HT1080 
cells that were either kept in suspension or plated on FN for 20 min in the absence of serum and fractionated into 100,000 g supernatant (cytosol) and 
pellet (P100; membrane) fractions. Levels of PIPKI-, Rac1, RhoGDI (cytosol), EGFR (plasma membrane), and tubulin (loading control) in the cell lysate and 
the P100 fraction were analyzed by SDS-PAGE and Western blot analysis. A representative experiment (n = 3) is shown. (G) Rac1 forms a stable complex 
with PIPKI-. Rac1 was immunoprecipitated (IP) from cells that were either kept in suspension in serum-free medium or plated on FN for 20 min. Rac1 and 
copurifying PIPKI- were detected by Western blot analysis using appropriate antibodies. IgG immunoprecipitates were probed as a negative control.   
A representative experiment is shown (n = 3). (H) Enforced Rac1 membrane targeting restores PDGF-induced Rac1 activation to PIPKI- knockdown cells. 
Quiescent control or PIPKI-–depleted HT1080 cells expressing Lyn-EGFP-Rac1 (Lyn-Rac1) were stimulated with 10 ng/ml PDGF (13’) or left untreated (0’). 
GTP-bound endogenous Rac1 or ectopically expressed Lyn-EGFP-Rac1 was isolated by pull-down assay using PBD-PAK1-GST. Total and GTP-bound levels 
of Rac1 and Lyn-EGFP-Rac1 were analyzed by Western blotting using antibodies directed against Rac1 and GFP, respectively.
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sequence from Lyn kinase (Kovárová et al., 2001) at its N ter-
minus. When Lyn-Rac1 was expressed in PIPKI-–depleted 
cells that were grown on FN and serum starved to exclude sig-
nals by growth factors, GTP loading occurred even in the ab-
sence of PIPKI- (Fig. 6 B). Subcellular fractionation of cell 
lysates showed that Lyn-Rac1 was present in the membrane 
fraction in PIPKI-–depleted cells (Fig. 6 C). This likely re-
flects the PIPKI-–independent targeting of Lyn-EGFP-Rac1   
to the plasma membrane, as indicated by immunofluorescence 
analysis  of  Lyn-EGFP-Rac1–expressing  PIPKI-–deficient 
cells (Fig. S5). Indeed, there appeared to be a close relationship 
between the extent of plasma membrane association and the ex-
tent of GTP loading. For example, Rac1 membrane association 
and GTP loading could also be restored in part by high level 
overexpression of wild-type Rac1 in PIPKI- knockdown cells 
(Fig. 6, C–E), presumably because Rac1 overexpression drives 
the localization of Rac1 to the membrane by mass action (Fig. S5) 
because of the presence of the C-terminal CAAX sequence.   
Indeed, a Rac1 variant containing a mutation in the C-terminal 
CAAX box that abrogates lipid modification failed to undergo 
GTP loading, and this mutant was also absent from the mem-
brane fraction and localized mainly to the nucleus (Fig. 6, C–E; 
and Fig. S5). Collectively, these findings are consistent with the 
idea that PIPKI- effects on GTP loading are secondary to its 
effects on Rac1 membrane localization.
PIPKI- has been reported to form a complex with Rac1 
in the cytoplasm (Tolias et al., 1998, 2000; van Hennik et al., 
2003). The question then arises whether integrins regulate the 
translocation of a PIPKI-–Rac1 complex to the membrane. 
Consistent with such a notion, we observed a concomitant   
Figure 7.  PIPKI- is required for directed cell migration. (A) Wound closure by PIPKI- knockdown cells is shown. Control or PIPKI-–depleted HT1080 
cells were scratch wounded, and closure of the cell-free area was followed by time-lapse microscopy. Representative still photographs taken at the indicated 
time points after scratching are shown. Bar, 200 µm. (B) Quantification of the cell-free area during tissue culture wound closure from A, relative closure 
of the cell-free area, is shown. (C) Trajectories of sparsely plated and randomly migrating cells were tracked by time-lapse microscopy over a 6-h period. 
10 trajectories of representative cells are shown. (D) Quantification of the directionality (persistence) of migration of individually migrating cells from C   
is shown. Persistence is calculated as the ratio (D/T) of the shortest distance from the initial to the last position (D) over the total length of the trajectory   
(T; n = 20). (E) PIPKI- knockdown effects on chemotaxis and haptotaxis. Cell migration of control or PIPKI-–depleted HT1080 cells across Transwell 
membranes was assayed in response to blank medium, serum (10% FBS), or 10 µg/ml FN present in the bottom chamber. Cells were incubated for 2 h 
at 37°C, and the total number of cells passing through the membrane was determined. Results shown are expressed as the percentage of migrated cells 
relative to control cells. Migration of control cells toward FBS was arbitrarily set to 100%. Error bars indicate SEM (n = 3).257 Type I PIPK- regulates Rac1 activation • Chao et al.
was analyzed (Fig. 7, C and D). Cells depleted for PIPKI- also 
failed to respond to two chemoattractants, serum or FN (Fig. 7 E), 
in Transwell migration assays and were defective in chemotaxis 
toward a stable gradient of PDGF (Fig. 8). These results show 
that PIPKI- is necessary for directional cell movement during 
random migration as well as during migration induced in re-
sponse to chemotactic or haptotactic stimuli.
Significantly, the chemotaxis defect of PIPKI-–depleted 
cells toward a gradient of PDGF could be suppressed by expres-
sion of Lyn-Rac1 and, to a lesser extent, of wild-type Rac1 (Fig. 8). 
These findings suggest that the requirement for PIPKI- in cell 
migration can be bypassed by increasing Rac1 plasma mem-
brane  levels.  Consistent  with  such  an  idea,  expression  of  a 
CAAX box–deleted Rac1 mutant that failed to target to the 
plasma membrane also failed to restore chemotaxis (Fig. 8). 
Notably, the migration defect associated with PIPKI- deple-
tion could also be partially rescued by expression of the kinase-
dead  PIPKI-  mutant  IKD  compared  with  the  wild-type 
protein (Fig. 8), a finding that is in line with our observation that 
PIPKI- controls Rac1 membrane translocation through a   
kinase-independent  mechanism.  Collectively,  these  results   
suggest that the modulation of Rac1 membrane targeting by 
PIPKI- is a key function through which PIPKI- controls di-
rectional  cell  migration,  but  PI4,5P2-dependent  mechanisms 
likely also contribute.
Depletion of PIPKI- confers defects in 
membrane ruffling and actin organization
Rac1 plays a central role in directed cell migration by induc-
ing lamellipodia extension and membrane ruffling (Nobes and 
Hall, 1999; Hall and Nobes, 2000). This is in part mediated by 
the  Rac1-dependent  recruitment  of  actin-binding  proteins 
such as cortactin to the leading edge and by the stimulation of 
Arp2/3-mediated actin polymerization. We found that migrat-
ing HT1080 cells depleted for PIPKI- showed markedly de-
creased membrane ruffling (Fig. 9 A) and appeared to produce 
multiple, unstable membrane protrusions in random directions 
when compared with control siRNA–treated cells (unpub-
lished data). Phalloidin staining of F-actin further revealed 
that the majority of PIPKI- knockdown cells (78 ± 5%; n = 100; 
P < 0.001) had lost actin-rich lamellae and showed a concomitant 
increase in PIPKI- and Rac1 levels in the membrane fraction 
after cell adhesion to FN (Fig. 6 F). Because similar levels of 
PIPKI- protein can be coimmunoprecipitated with Rac1 in 
suspended and adherent HT1080 cells (Fig. 6 G), these results 
are best explained by a model wherein PIPKI- forms a stable 
complex with Rac1 in the cytosol that translocates to the plasma 
membrane in response to integrin activation.
Interestingly,  we  also  observed  GTP  loading  of  Lyn-
Rac1 but not of endogenously expressed Rac1 in response to 
PDGF stimulation of PIPKI-–depleted cells (Fig. 6 H). This 
may indicate that PIPKI- also regulates PDGF-induced acti-
vation of Rac1 by controlling its membrane targeting. Consis-
tent with such a notion, Rac1 translocation to the membrane 
can also be induced in response to serum stimulation of cells 
(Hansen and Nelson, 2001). Whatever the precise mechanism, 
these data show that Rac1-GTP loading can occur in the ab-
sence of PIPKI- once efficient Rac1 plasma membrane local-
ization is restored.
PIPKI- is necessary for directional  
cell migration
To establish the physiological significance of the Rac1–PIPKI- 
interaction, we examined whether Rac1-regulated cellular pro-
cesses are impaired in PIPKI-–depleted cells. Previous studies 
have shown that Rac1 deficiency causes defects in the direc-
tional persistence of cell migration in many cell types (Glogauer 
et al., 2003; Sun et al., 2004; Pankov et al., 2005). Therefore,   
we examined directional cell migration in PIPKI-–deficient 
HT1080 cells. Scratch wound assays showed that PIPKI-– 
depleted HT1080 cells were significantly less motile than   
control  siRNA–treated  cells  (58  ±  2%  reduction;  Fig.  7,   
A and B). Tracing of migration tracks of individual cells by 
time-lapse digital microscopy further revealed that the reduc-
tion in wound closure rates in PIPKI- knockdown cells was 
mainly the result of a decrease in directional persistence (50% 
decrease; n = 20; P < 0.001), although a modest decrease in 
mean migration velocity was also observed (control cells, 36.0 ±   
1.6 mm/h; PIPKI- knockdown cells, 27.2 ± 2.3 mm/h; 25% 
decrease; n = 20; P < 0.001). The inhibition of directional per-
sistence  was  even  more  pronounced  when  the  migration  of 
sparsely seeded, individually migrating PIPKI-–depleted cells 
Figure 8.  Membrane-targeted Rac1 suppresses the 
chemotaxis defect of PIPKI- knockdown cells. Chemo-
taxis in response to a stable gradient of 10 µg/ml 
PDGF quiescent control or PIPKI-–depleted HT1080 
cells transfected with empty vector or vectors containing 
the indicated cDNAs. Chemotaxis was measured using 
µ-slide chemotaxis chambers. Results are shown as the 
percentage of migrated cells relative to control cells. 
Error bars indicate means ± SD (n = 3). Transfection 
efficiency was 85% based on GFP fluorescence.JCB • VOLUME 190 • NUMBER 2 • 2010   258
RNAi–treated cells, these cells failed to extend lamellipodia, and 
only a small fraction of cells spread within a 1-h period, whereas 
control RNAi–treated cells were fully spread within 30 min after 
plating (Fig. 10 B). Together, these data suggest that PIPKI- regu-
lates the kinetics of cell spreading and integrin-mediated formation 
of cell–matrix contacts. Because focal complexes in the extending   
membrane protrusion are important for the formation of a stable   
lamellipodium, the impaired assembly of focal contacts may con-
tribute to the cell migration defects of PIPKI- knockdown cells.
Importantly, the focal adhesion phenotype of PIPKI-–
depleted cells was rescued by expression of Lyn-Rac1 because 
60 ± 2% of cells expressing the plasma membrane–anchored 
Lyn-Rac1 variant were fully spread compared with 22 ± 2.5% 
of cells expressing vector alone (Fig. 10, B and C). Notably, 
Lyn-Rac1 also restored membrane ruffling to PIPKI- knock-
down cells (Fig. 10 B). Together, these data suggest that PIPKI-–
depleted cells have impaired membrane ruffling and defects in 
cell spreading and focal adhesion formation because of defec-
tive Rac1 signaling. Collectively, these results support the no-
tion that PIPKI- is an important regulator of Rac1 activity 
during directed cell migration.
Discussion
Integrin receptors have been shown to spatially regulate Rac1 
signaling  by  controlling  Rac1  membrane  targeting  (Price   
et al., 1998; del Pozo et al., 2000, 2002; Kraynov et al., 2000); 
increase in actin stress fibers and cortical actin bundles (Fig. 9 B). 
Consistent with these alterations in actin morphology, cortac-
tin and the Arp2/3 complex subunit Arp3 failed to localize to 
the  plasma  membrane  in  PIPKI-–depleted  cells,  whereas 
>90% of control siRNA–treated cells contained prominent   
lamellipodial ruffles enriched in F-actin, cortactin, and Arp3 
(Fig. 9, B and C). Notably, serum-starved PIPKI- knock-
down cells failed to induce actin-rich membrane ruffles in re-
sponse to PDGF stimulation, whereas such structures were 
readily observed in control cells (Fig. 9 D). Collectively, these 
results suggest that PIPKI- plays a central role in actin cyto-
skeletal reorganization and membrane ruffling. These data 
therefore support the notion that Rac1 activity is impaired in 
PIPKI-–depleted cells.
Depletion of PIPKI- confers defects in 
focal adhesion formation and cell spreading
Rac1 is also important for cell spreading and the formation of 
focal adhesion contacts (Nobes and Hall, 1999; Hall and Nobes, 
2000). Analysis of the distribution of focal adhesion markers, 
including vinculin and talin, in PIPKI-–depleted cells showed 
that the number of adhesion plaques was significantly reduced in 
these cells compared with control siRNA–treated cells (Fig. 10 A). 
This suggests that focal adhesion formation or stability is   
impaired in PIPKI-–depleted cells.
Moreover, although PIPKI- knockdown cells adhered   
to FN within a 10-min period in a manner similar to control   
Figure 9.  Knockdown of PIPKI- leads to de-
fects in membrane ruffling and F-actin organi-
zation. (A) Leading edge membrane ruffles are 
decreased in migrating PIPKI-–depleted cells 
but not in control siRNA–treated cells. HT1080 
cells,  transfected  with  the  indicated  siRNAs, 
were stimulated to migrate by scratch wounding 
and monitored by video microscopy. Represen-
tative still pictures are shown. Arrows identify 
leading  edge  membrane  ruffles.  (B  and  C)   
Distribution of F-actin, cortactin, and Arp3   
in PIPKI-–depleted HT1080 cells. (top) Cells 
were fixed and stained with Alexa Fluor 594 
phalloidin  to  visualize  F-actin.  Endogenous 
cortactin  (B)  or  Arp3  (C)  was  visualized  by 
indirect immunofluorescence using mouse anti-
cortactin and anti-Arp3 antibodies followed by 
Cy2-conjugated  goat  anti–mouse  antibodies 
(bottom).  (D)  PDGF  induced  F-actin  distribu-
tion  in  PIPKI-  knockdown  cells.  Quiescent 
control or PIPKI-–depleted HT1080 cells were 
stimulated with 10 ng/ml PDGF (bottom; +) or 
left untreated (top; ). Cells were fixed and 
stained for F-actin with Alexa Fluor 594 phal-
loidin. (B–D) Representative examples (n = 3)   
of cells are shown. Arrows indicate plasma mem-
brane areas  containing  F-actin,  cortactin,  or 
Arp3 signal. Bars, 10 µm.259 Type I PIPK- regulates Rac1 activation • Chao et al.
In summary, our study describes a novel, kinase-independent 
role of PIPKI- in directed cell migration and suggests that 
PIPKI- orchestrates this process by spatially regulating Rac1 
however, the mechanism by which this occurs and the resulting 
implications for cell migration have so far not been described. 
The data presented in this study identify PIPKI- as a mediator 
of Rac1 membrane targeting and show that PIPKI- thereby 
regulates  Rac1  activation  and  downstream  signaling. This   
conclusion  is  based  on  (a)  the  characterization  of  PIPKI- 
knockdown phenotypes, which shows that PIPKI- modulates 
Rac1-dependent cellular processes such as actin and focal adhe-
sion dynamics and the directional persistence of cell migration, 
and (b) the finding that all PIPKI-–associated phenotypes can 
be suppressed by plasma membrane–anchored Rac1.
Notably, the role of PIPKI- in Rac1 targeting is isoform 
specific, appears to require physical interaction with the poly-
basic domain of Rac1, and is independent of catalytic activity. 
Therefore,  PIPKI-  appears  to  have  two  major  signaling   
roles: a scaffolding role that serves to target Rac1 and a role as 
a lipid kinase to generate PI4,5P2. The finding that enforced 
targeting of Rac1 to the plasma membrane is able to bypass 
the requirement for PIPKI- and suppresses the chemotaxis 
defect  of  PIPKI-  knockdown  cells,  further  suggesting   
that the scaffolding role of PIPKI- plays an important role in 
cell migration. These data therefore provide evidence for a 
new mechanism for the spatial regulation of Rac1 activity. 
This mechanism can operate independently and in addition   
to  PI4,5P2  and  PI3,4,5P3  gradients  and  modulate  directed   
cell migration.
Our  data  show  that  PIPKI-  accumulates  at  plasma 
membrane sites where local activation of integrin receptors 
occurs. Because activated integrins are more prominent at   
the front of migrating cells (Moissoglu and Schwartz, 2006), 
integrin activation may lead to the preferential recruitment of 
PIPKI- and, consequently, Rac1 to this site. Therefore, a key 
question is how activated integrins regulate the translocation 
of PIPKI- to the plasma membrane. Previous studies have 
implicated Ajuba, a LIM domain–containing protein neces-
sary for Rac1 activation and directed cell migration, in the   
targeting of PIPKI- to lamellipodia and membrane ruffles 
(Doughman et al., 2003; Kisseleva et al., 2005). Thus, Ajuba 
is  a  plausible  candidate  for  mediating  integrin-dependent 
membrane translocation of PIPKI-.
The finding that PIPKI- in an upstream regulator of Rac1 
in cell migration appears to contradict earlier reports, which iden-
tified PIPKI- as an effector of small GTPases in growth factor– 
and G protein–coupled receptor pathways (Chatah and Abrams, 
2001; Doughman et al., 2003). However, earlier studies were per-
formed by overexpression of wild-type and dominant-negative 
PIPKI variants in conjunction with expression of constitutively 
active or dominant-negative Rac1 mutants (Chatah and Abrams, 
2001; Doughman et al., 2003). Although these types of ap-
proaches have revealed roles of PIPKI isoforms in the regulation 
of many cellular processes, they have limitations and may not ac-
curately reflect the function or localization of the endogenous 
PIPKI proteins and their relationship with members of the small 
GTPase family. In contrast, RNAi has emerged as a specific and 
effective means to test the physiological roles of individual PIPKI 
isoforms, although these approaches produce hypomorph and not 
complete loss of function phenotypes.
Figure 10.  PIPKI- depletion impairs focal adhesion formation and cell 
spreading. (A) Control or PIPKI-–depleted HT1080 cells were plated on 
FN substrate, fixed, and stained for vinculin or talin using specific mono-
clonal antibodies to reveal focal adhesions (arrows). (B) Expression of 
membrane-targeted Rac1 rescues the focal adhesion and spreading de-
fects of PIPKI-–depleted cells. Control or PIPKI-–depleted HT1080 cells 
expressing Lyn-EGFP-Rac1 (Lyn-Rac1) or containing empty vector were re-
suspended and plated on FN substrate. After 45 min, cells were fixed 
and stained for vinculin to reveal focal adhesions. F-actin was visualized 
with Alexa Fluor phalloidin, and GFP fluorescence was recorded directly. 
Transfection efficiency was 80% based on GFP fluorescence. (C) Cells 
were treated as in B and assayed for cell spreading. A quantification of 
the results is shown in which spreading is expressed as the percentage 
of adherent cells to total cells. Error bars indicate means ± SD (n = 3).   
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The  following  siGENOME  SMARTpool  reagents  were  used:  PIPKI-, 
M004780-02-0010; PIPKI-, M004058-00-0005; Rac1, M003560-02-
0002; and scrambled siCont, D-001810-10-05. siRNA pools were trans-
fected  at  a  concentration  of  20  nM  into  30–50%  confluent  HeLa  or 
HT1080 cells grown on 24-well plates in normal growth medium without 
antibiotics using Lipofectamine 2000 (Invitrogen) as recommended by 
the manufacturer. siRNA-treated cells were analyzed 48 h after trans-
fection for knockdown efficiency by Western blot analysis and for spe-
cific phenotypes.
Immunofluorescence and pixel intensity profiles
Cells grown on glass coverslips were fixed with 3.7% formaldehyde, per-
meabilized  in  0.2%  Triton  X-100,  and  incubated  with  primary  (1:50– 
1:100  dilution  in  PBS/0.1%  Triton  X-100)  and  appropriate  secondary 
antibodies (1:200 dilution in PBS/0.1% Triton X-100). Coverslips were 
washed in PBS and mounted with gel mount aqueous mounting medium 
(Sigma-Aldrich). Images were acquired at room temperature using a con-
focal microscope (LSM 510 META; Carl Zeiss, Inc.) with a 40× 1.0 NA oil 
objective (Carl Zeiss, Inc.) and 2× zoom in magnification. Images were im-
ported into Photoshop (version 8.0; Adobe) for processing. The degree of 
colocalization in immunostainings was determined by superposition of   
images acquired in the different channels (488, 594, and 647 nm). Line 
scans of fluorescence intensity were performed using the intensity profile 
function of the software (LSM 510; Carl Zeiss, Inc.).
Determination of Rac1-GTP levels
Rac1-GTP levels were analyzed 48 h after siRNA transfection from cell ly-
sates using pull-down assays with a GST fusion protein containing the PBD 
domain of human PAK exactly as described previously (Benard and Bokoch, 
2002). For determination of Rac1-GTP levels in PDGF-treated cells, cells 
were starved for 18 h in serum-free DME and treated with 10 ng/ml PDGF 
for 13 min before analysis. Adhesion-induced Rac1-GTP levels were mea-
sured exactly as described previously (del Pozo et al., 2002). Bound Rac1-
GTP and total Rac1 present in cell lysates were analyzed by SDS-PAGE and 
Western blotting with a mouse anti-Rac1 antibody followed by HRP- 
conjugated anti–mouse secondary antibodies. For determination of Lyn-Rac1-
GTP levels, cells were transfected with the Lyn-EGFP-Rac1 expression vector 
24 h after siRNA treatment, and GTP levels were determined 24 h by GST-PAK 
pull-down from lysates. Precipitates were analyzed by SDS-PAGE and West-
ern blotting with mouse anti-EGFP antibody followed by HRP-conjugated 
anti–mouse secondary antibodies. Blots were developed using an enhanced 
chemiluminescence system. Rac1 levels of at least three independent experi-
ments were quantified by scanning densitometry using the Image Gauge 
program (version 4.0; Fujifilm), and multiple exposures of each gel were an-
alyzed. In each experiment, Rac1-GTP levels were normalized against total 
Rac1 in the cell lysate.
Bead recruitment assays
HeLa cells were grown on coverslips and either left untreated or transfected 
with control siRNAs or siRNAs directed at PIPKIs or Rac1. 48 h after trans-
fection, cells were incubated with 5 µm polystyrene divinylbenzene beads 
at 37°C for 20 min at a cell to bead ratio of 1:40 as described previously 
(del Pozo et al., 2002). Beads were coated with heat-treated 10 mg/ml 
BSA or 10 µg/ml FN at 4°C overnight exactly as described previously   
(del Pozo et al., 2002). Pixel intensity profiles across lines were used to ana-
lyze the extent of colocalization.
Subcellular fractionation
Cells grown on 10 µg/ml FN were transfected with control siRNAs or siRNAs 
targeting I or Rac1. 48 h after transfection, cells were serum starved for 
2 h to eliminate contributions from growth factors. Cell lysates were gener-
ated and subfractionated into 100,000 g pellet (P100) or supernatant 
(S100) fractions exactly as described previously (del Pozo et al., 2002). 
Typically, 20 µg total protein from each fraction, representing 5% of cyto-
sol fraction and 20–50% of the membrane fraction, was analyzed by 
Western blotting. Blots were quantified by scanning densitometry as   
described above.
Mitochondrial targeting assay
HeLa  cells  were  cotransfected  with  either  EGFP-OMP25–PIPKI-,  EGFP-
OMP25–PIPKI-KD, or EGFP-OMP25–PIPKI- and plasmids containing Flag-
tagged wild-type and mutant Rac1 variants as indicated. 24 h after 
transfection, cells were fixed and analyzed by indirect immunofluorescence 
using mouse monoclonal anti-Flag antibodies followed by Cy3-conjugated 
goat anti–mouse IgGs. Actin was visualized by Alexa Fluor 647–conjugated 
phalloidin.  EGFP-OMP25  fusions  were  visualized  by  488-nm  excitation. 
activity. Interestingly, recent knockout and RNAi studies have 
demonstrated that PIPKI- and PIPKI- play distinct roles dur-
ing Fc receptor–mediated phagocytosis: PIPKI- acts upstream 
of Rac1 and RhoA, whereas PIPKI- promotes N-WASP (neural 
Wiskott-Aldrich syndrome protein) activation and N-WASP– 
dependent de novo actin polymerization (Mao et al., 2009). 
Moreover, additional isoform-specific roles for PIPKI- and   
the PIPKI-661 splice variant in the regulation of cell polari-
zation and directed cell migration have been reported previ-
ously (Lacalle et al., 2007; Lokuta et al., 2007; Sun et al., 2007). 
Thus, all PIPK isoforms appear to contribute to the regulation 
of actin dynamics and cell migration but display remarkable 
specificity in their signaling roles, and a major focus of future 
research should be to understand the basis for this specificity.
Materials and methods
Cell culture
Human cervical carcinoma and human fibrosarcoma HT1080 cell lines 
(American Type Culture Collection) were grown in DME supplemented with 
10% calf serum, penicillin, and streptomycin (Invitrogen) with 5% CO2  
at 37°C.
Antibodies and reagents
Isoform-specific polyclonal rabbit anti–PIPKI- and anti–PIPKI- antibodies 
were generated against the C-terminal PIPKI tails and were affinity purified 
before use. Anti–PIPKI-–pan antibodies were provided by P. de Camilli 
(Yale University, New Haven, CT). Rabbit anti-HA antibodies were ob-
tained  from  BabCo,  mouse  anti-Rac1  clone  102,  mouse  anti-cortactin, 
mouse anti-EGFR, and mouse anti-RhoGDI antibodies were obtained from 
BD, and mouse anti-Arp3 antibodies were obtained from Abcam. Cy2- 
and Cy3-conjugated goat anti–mouse and Cy2-conjugated goat anti– 
rabbit IgGs were obtained from Jackson ImmunoResearch Laboratories, 
Inc.  Alexa  Fluor–conjugated  phalloidin  was  obtained  from  Invitrogen. 
LY294002 and neomycin were obtained from Enzo Life Sciences, Inc.
Plasmid constructs
We used the human PIPKI nomenclature throughout the manuscript, which 
is different from the mouse designation, as human and mouse PIPKI- and 
PIPKI- isoforms were named in a reciprocal manner; i.e., human PIPKI- 
corresponds to mouse PIPKI- and vice versa (Ishihara et al., 1996; Loijens 
and Anderson, 1996). Plasmids containing epitope-tagged wild-type PIPKI-, 
PIPKI-, PIPKI-635, PIPKI-661, and the kinase-dead IKD mutant (PIPK I; 
D309N and R427Q) were previously described (Coppolino et al., 2002). 
GST-PAK-BD was obtained from G. Bokoch (The Scripps Research Institute, 
La Jolla, CA). Rac1 and Rac1
V12 cDNAs in pRK5 were provided by A. Hall 
(Memorial Sloan-Kettering Institute, New York, NY). K-Ras4B, Rac2, and 
Rac3 cDNAs were obtained from E. Chang (Baylor College of Medicine, 
Houston, TX), D.A. Williams (Cincinnati Children’s Foundation, Cincinnati, 
OH), and N. Heisterkamp (Childrens Hospital of Los Angeles, Los Angeles, 
CA), respectively. pEGFP-WAVE2 was generated by PCR amplification of 
WAVE2 from plasmid pEF-BOS-FLAG-WAVE2 (provided by T. Takenawa, 
University of Tokyo, Tokyo, Japan). Plasmids EGFP-OMP25 (Nemoto and 
De Camilli, 1999) and EGFP-OMP25 containing human HA-tagged PIPKI-
661 were obtained from P. de Camilli. The Lyn-EGFP plasmid was pro-
vided by T. Meyer (Stanford University, Palo Alto, CA). Point mutations and 
chimeras were created using the QuikChange site-directed mutagenesis kit 
(Agilent Technologies) according to the manufacturer’s protocol and cloned 
into Escherichia coli and mammalian expression vectors. For construction 
of I-Mito and IKD-Mito, the open reading frames of PIPKI- and PIPKI-
KD  were  amplified  by  PCR,  digested  with  appropriate  restriction  en-
zymes, and cloned in frame into the polylinker between EGFP and OMP25 
in EGFP-OMP25. For construction of Lyn-Rac1, the open reading frame en-
compassing wild-type Rac1 was obtained by PCR and ligated into the 
polylinker of the pcDNA3-Lyn-EGFP vector. All constructs and mutations 
were confirmed by DNA sequencing.
RNAi
siRNA SMARTpool reagents (a mixture of four oligonucleotides specific 
for each targeted gene) were purchased from Thermo Fisher Scientific. 261 Type I PIPK- regulates Rac1 activation • Chao et al.
via the polybasic tail of Rac1. Fig. S4 shows that mitochondrial target-
ing of PIPKI- affects Rac1 subcellular localization and chemotaxis. Fig. S5   
shows targeting of GFP-tagged Rac1 variants in PIPKI-–depleted cells. Online   
supplemental  material  is  available  at  http://www.jcb.org/cgi/content/ 
full/jcb.200911110/DC1.
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